# US Uterine Fibroid Treatment Device Market > US Uterine Fibroid Treatment Device Market Research Report By Technology (Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques) and By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment, Non-invasive Treatment) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.21% - **2024:** $ 1,547.08 Million - **2025:** $ 1,705.03 Million - **2035:** $ 4,507.52 Million - **Key Players:** Medtronic (US), Boston Scientific (US), Hologic (US), Abbott (US), Johnson & Johnson (US), Stryker (US), Bayer (DE), Merck (DE), Siemens Healthineers (DE) **Report ID:** MRFR/HC/17420-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-uterine-fibroid-treatment-device-market-18966 --- ## Market Summary ## **US Uterine Fibroid Treatment Device Market Overview** As per MRFR analysis, the US Uterine Fibroid Treatment Device Market Size was estimated at 1.4 (USD Billion) in 2023. The US Uterine Fibroid Treatment Device Market Industry is expected to grow from 1.55(USD Billion) in 2024 to 4.5 (USD Billion) by 2035. The US Uterine Fibroid Treatment Device Market CAGR (growth rate) is expected to be around 10.208% during the forecast period (2025 - 2035). ### **Key US Uterine Fibroid Treatment Device Market Trends Highlighted** The US Uterine Fibroid Treatment Device Market is experiencing significant transformation driven by several key factors. An increasing awareness of women's health issues and the importance of innovative treatment options for uterine fibroids is a primary market driver. As more women seek alternatives to traditional surgical procedures, there is a growing demand for non-invasive and minimally invasive treatment options, fostering the development of advanced devices in this field. Additionally, the rising prevalence of uterine fibroids among women of reproductive age in the US reflects a pressing need for effective management solutions, which supports the push for new technologies. Opportunities in this market are presented by the expansion of research and development initiatives focused on novel treatment modalities, including radiofrequency ablation and uterine artery embolization. The adoption of telemedicine and digital health technologies is also transforming patient access to care and support, facilitating more personalized treatment plans for women. By tapping into these innovations, manufacturers can strengthen their positions and meet the evolving demands of healthcare providers and patients alike. In recent times, trends such as increased investment in clinical trials and a focus on patient-centered care are emerging as vital components of the market landscape. The US healthcare system is placing greater emphasis on evidence-based practices and regulatory approvals that ensure patient safety and efficacy in treatment options. This trend indicates a shift towards integrating patient feedback and outcomes into product development processes. Consequently, a combination of technological advancements, evolving patient needs, and regulatory support are playing crucial roles in shaping the future of the US Uterine Fibroid Treatment Device Market. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **US Uterine Fibroid Treatment Device Market Drivers** ### **Rising Awareness and Diagnosis of Uterine Fibroids** The increasing awareness regarding uterine fibroids among the general population is significantly driving the US [Uterine Fibroid Treatment Device Market](../../../reports/uterine-fibroid-treatment-device-market-12068) Industry. According to the Centers for Disease Control and Prevention (CDC), it is estimated that between 20% to 80% of women will develop uterine fibroids by the age of 50. This growing awareness leads to more women seeking medical advice and undergoing diagnostic procedures such as ultrasounds and MRIs to detect fibroids. Furthermore, the implementation of public health campaigns by organizations like the American College of Obstetricians and Gynecologists (ACOG) has also contributed to the early diagnosis and management of this condition. The rise in diagnosed cases creates a substantial market opportunity for treatment devices, leading to market growth as healthcare providers gain access to efficient treatment technologies to address the increasing patient population. ### **Advancements in Treatment Technology** Technological advancements in the treatment of uterine fibroids are a major driving force in the US Uterine Fibroid Treatment Device Market Industry. Innovative procedures such as magnetic resonance-guided focused ultrasound (MRgFUS) and minimally invasive surgical options have revolutionized the treatment landscape. According to the American Institute of Ultrasound in Medicine, the use of focused ultrasound for fibroid treatment has seen an increase of over 50% in application due to its non-invasive nature. Leading manufacturers like Hologic Inc. and Siemens Healthineers are at the forefront of these technological advancements, continuously enhancing their product offerings to align with modern medical practices. As patients increasingly opt for minimally invasive procedures, the demand for advanced treatment devices is expected to rise, contributing to market expansion. ### **Government Initiatives and Funding for Women's Health** Government initiatives aimed at improving women's health are significantly contributing to the growth of the US Uterine Fibroid Treatment Device Market Industry. The Women’s Health Initiative, funded by the National Institutes of Health (NIH), provides substantial financial support for research related to women’s health, including the study of uterine fibroids. With an increase in funding, researchers and companies are focusing on the development of more effective uterine fibroid treatment options. Moreover, policies aimed at increasing insurance coverage for fibroid treatments facilitate access to necessary procedures for a larger patient base, further driving market growth. The positive impact of these initiatives amplifies consumer confidence in seeking treatment and contributes to the overall expansion of the market. ## **US Uterine Fibroid Treatment Device Market Segment Insights** ### **Uterine Fibroid Treatment Device Market Technology Insights** Meanwhile, Laparoscopic Techniques have gained traction due to their minimally invasive nature, resulting in lesser pain and quicker recovery times. The increasing demand for outpatient procedures is driving the popularity of these techniques, as they are generally associated with reduced hospital stays and lower risks of complications. Ablation Techniques offer another dimension to the Uterine Fibroid Treatment Device Market, focusing on the destruction of fibroid tissues using energy sources to alleviate symptoms effectively. These techniques cater to a growing patient base seeking less invasive options that align with a desire for minimal recovery time. The growing preference for personalized treatment plans further solidifies the significance of As the healthcare landscape evolves in the US, the integration of Ablation Techniques reflects a commitment to advancing patients’ experiences and choices in managing their reproductive health. Lastly, Embolization Techniques have also emerged as a significant player in the treatment arsenal, utilizing directed therapy to block blood supply to fibroids and induce their reduction in size.  The choice of embolization is becoming increasingly prevalent among women, as it offers a non-surgical alternative that results in effective symptom control. With government initiatives to improve women’s health care and increase awareness about uterine fibroids, these technology areas represent a vital cog within the US Uterine Fibroid Treatment Device Market, promising opportunities for research and innovation. Emphasizing advancements and emerging techniques will continue to shape treatment paradigms, aligning with the wider trends of patient empowerment within the healthcare continuum. As healthcare professionals tailor their approaches to meet the demands of an evolving patient demographic, the importance of these various technologies becomes increasingly evident in establishing effective and patient-centered care models. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Uterine Fibroid Treatment Device Market Mode of Treatment Insights** Conversely, Minimally Invasive treatments have gained popularity due to their effectiveness while involving fewer complications and shorter hospital stays, making them attractive to both patients and healthcare providers. Non-invasive treatments, such as focused ultrasound and medication management, appeal to patients seeking alternatives that avoid surgery altogether. This segment is essential as it often reflects the trends toward patient-centered care, emphasizing safety and recovery. The US market for uterine fibroid treatments consistently shows a preference for approaches that reduce downtime and improve the quality of life for women, driven by increasing awareness and advancements in medical technology. As healthcare professionals seek to provide personalized treatment plans, the Mode of Treatment within the US Uterine Fibroid Treatment Device Market plays a crucial role in shaping patient outcomes and industry growth. ## **US Uterine Fibroid Treatment Device Market Key Players and Competitive Insights** The US Uterine Fibroid Treatment Device Market is a rapidly evolving landscape driven by advancements in medical technologies and a growing understanding of uterine fibroids and their impact on women's health. This market is characterized by a range of devices and treatments designed to address fibroid symptoms, enhance patient outcomes, and provide alternatives to traditional surgical interventions. As awareness of these conditions increases among healthcare providers and patients alike, there is a heightened demand for minimally invasive procedures, contributing to the competitive dynamics of the market. The interplay between established manufacturers, emerging companies, and technological innovations forms the core of competitive insights within this sector. Smith and Nephew has carved a significant niche within the US Uterine Fibroid Treatment Device Market, leveraging its strong reputation for quality and reliability. The company is well-regarded for its strategic focus on product innovation and commitment to improving women's health outcomes. Its ability to provide comprehensive solutions that cater specifically to the needs of healthcare professionals and patients enables it to maintain a substantial presence in the market. Smith and Nephew's strengths lie in its advanced technologies that facilitate minimally invasive procedures, enhancing recovery times and providing effective treatment options. The company actively engages with physicians to continuously refine its offerings, ensuring that it remains competitive and responsive to market demands. Hologic plays a formidable role in the US Uterine Fibroid Treatment Device Market, known for its robust portfolio of healthcare solutions aimed at diagnosing and treating women's health conditions. Hologic's key products include advanced imaging systems and minimally invasive surgical devices, which are pivotal in the management of uterine fibroids. The company's commitment to research and development has led to a strong market presence, bolstered by strategic partnerships and acquisitions that expand its capabilities and offerings. Hologic's strengths are reflected in its innovative technologies that enhance diagnosis accuracy and treatment effectiveness. The company's focus on improving patient experience and outcomes, paired with its proactive approach to engaging with healthcare professionals, positions Hologic as a leader in the market, effectively addressing the evolving needs of women in the US facing uterine fibroid challenges. ### **Key Companies in the US Uterine Fibroid Treatment Device Market Include** ## **US Uterine Fibroid Treatment Device Market Industry Developments** The US Uterine Fibroid Treatment Device Market has seen notable developments recently, particularly with advancements in minimally invasive technologies. Companies like Hologic and Medtronic have been focusing on enhancing their product offerings for uterine fibroid treatment, driving market growth. In September 2023, it was reported that Boston Scientific expanded its product portfolio with a new device aimed at effective fibroid management, which has positively impacted their market valuation. Current affairs indicate a growing emphasis on personalized medicine, influencing companies such as Stryker and Merit Medical Systems to invest in Research and Development initiatives tailored for individualized treatment solutions. Recent merger and acquisition activities in this sector include Johnson and Johnson's acquisition of a start-up specializing in uterine health devices in August 2023, enhancing their strategic positioning in the market. The increase in healthcare expenditure in the US, particularly for women's health, has further propelled the market's expansion. Historical developments, such as the FDA's approval in April 2022 for innovative fibroid treatment devices, underscore the evolving landscape, reinforcing market players' commitment to advancing therapeutic options for patients suffering from uterine fibroids. ## **US Uterine Fibroid Treatment Device Market Segmentation Insights** ### **Uterine Fibroid Treatment Device Market Technology Outlook** ### **Uterine Fibroid Treatment Device Market Mode of Treatment Outlook** ## Market Drivers ### Rising Incidence of Uterine Fibroids The increasing prevalence of uterine fibroids among women in the US is a primary driver for the uterine fibroid-treatment-device market. Studies indicate that approximately 70-80% of women will develop fibroids by the age of 50. This rising incidence necessitates effective treatment options, thereby propelling demand for innovative devices. As awareness of fibroid-related symptoms grows, more women seek medical intervention, further stimulating market growth. The uterine fibroid-treatment-device market is expected to expand as healthcare providers adopt advanced technologies to address this common condition. The financial implications are notable, with the market projected to reach $2 billion by 2026, reflecting the urgent need for effective solutions to manage fibroid symptoms. ### Growing Focus on Women's Health Initiatives The heightened focus on women's health initiatives in the US is driving the uterine fibroid-treatment-device market. Government and non-profit organizations are increasingly advocating for awareness and education regarding women's health issues, including uterine fibroids. This emphasis on women's health is likely to lead to more funding for research and treatment options, thereby expanding the market. As initiatives promote early detection and treatment, more women are expected to seek medical advice, increasing the demand for effective treatment devices. The uterine fibroid-treatment-device market stands to benefit from this trend, as it aligns with broader efforts to improve healthcare outcomes for women across the nation. ### Regulatory Support for Innovative Treatments Regulatory support for innovative medical treatments is a significant driver for the uterine fibroid-treatment-device market. The US Food and Drug Administration (FDA) has streamlined the approval process for new medical devices, encouraging manufacturers to develop and introduce advanced treatment options for uterine fibroids. This regulatory environment fosters innovation, allowing for quicker access to cutting-edge technologies that can improve patient care. As a result, the uterine fibroid-treatment-device market is likely to see an influx of new products that meet the evolving needs of patients. The potential for expedited approvals could lead to a market growth rate of 10% annually, reflecting the positive impact of regulatory support on device innovation. ### Advancements in Minimally Invasive Techniques The shift towards minimally invasive surgical techniques is significantly influencing the uterine fibroid-treatment-device market. These techniques, which include laparoscopic and robotic-assisted surgeries, offer patients reduced recovery times and lower complication rates compared to traditional surgical methods. As healthcare providers increasingly adopt these advanced technologies, the demand for specialized devices is likely to rise. The market for minimally invasive procedures has shown a growth rate of approximately 15% annually, indicating a robust trend towards less invasive treatment options. This evolution in surgical practices not only enhances patient outcomes but also drives the uterine fibroid-treatment-device market towards innovative solutions that align with patient preferences for less invasive care. ### Increased Investment in Healthcare Technology Investment in healthcare technology is a crucial driver for the uterine fibroid-treatment-device market. With the US healthcare system increasingly prioritizing technological advancements, funding for research and development in medical devices has surged. This influx of capital enables manufacturers to innovate and improve existing treatment devices, enhancing their efficacy and safety. The uterine fibroid-treatment-device market benefits from this trend, as new technologies emerge that cater to the specific needs of patients suffering from fibroids. In 2025, the healthcare technology sector is projected to reach $500 billion, with a significant portion allocated to developing devices for conditions like uterine fibroids, thereby fostering market growth. ## Future Outlook The [Uterine Fibroid Treatment Device Market](https://www.marketresearchfuture.com/reports/uterine-fibroid-treatment-device-market-12068) is projected to grow at a 10.21% CAGR from 2025 to 2035, driven by technological advancements and increasing patient awareness. **New opportunities:** - Development of AI-driven diagnostic tools for early detection. - Expansion of telehealth services for remote consultations. - Introduction of minimally invasive surgical devices to enhance patient recovery. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Technology: Ablation Techniques (Largest) vs. Laparoscopic Techniques (Fastest-Growing) The US uterine fibroid-treatment-device market showcases distinct preferences among various technology segments. Currently, Ablation Techniques hold the largest share due to their minimally invasive nature and the rising demand for patient-friendly procedures. Surgical Techniques, while still relevant, occupy a smaller portion of the market as newer technologies advance. Laparoscopic Techniques are gaining traction, indicating a shift towards less invasive solutions. Growth trends indicate a robust trajectory for Laparoscopic Techniques, with healthcare professionals increasingly adopting them for their effectiveness and lower complication rates. Factors such as advancements in technology, greater awareness, and improved patient outcomes play a role in driving the market. The demand for non-invasive treatments continues to grow, aligning with global healthcare trends focusing on patient-centered care. Ablation Techniques: Dominant vs. Laparoscopic Techniques: Emerging Ablation Techniques are characterized by their ability to remove or destroy fibroids with minimal downtime, making them the preferred choice among patients. Their dominance in the market is attributed to their effectiveness and patient satisfaction rates. On the other hand, Laparoscopic Techniques are emerging as a significant player due to advancements in surgical equipment and techniques that promote quicker recovery and reduced hospital stays. These two approaches provide distinct advantages, with Ablation Techniques leading in market share while Laparoscopic Techniques are poised for rapid growth as the healthcare sector evolves towards minimally invasive treatment options. ### By Mode of Treatment: Invasive Treatment (Largest) vs. Minimally Invasive Treatment (Fastest-Growing) In the US uterine fibroid-treatment-device market, the distribution of market share among the modes of treatment reveals that invasive treatment remains the largest segment, capturing a significant portion of the market. Following this, minimally invasive treatments are gaining traction, appealing to patients seeking alternatives with reduced recovery times. Non-invasive treatments, while popular, are comparatively smaller in terms of market share but are essential for comprehensive treatment options available to patients. In recent years, the trend towards minimally invasive treatment options has surged, driven by patient preferences for quicker recovery and less postoperative pain. Technological advancements in medical devices are also propelling growth, as they facilitate more effective and safer procedures. The awareness and education surrounding various treatment options continue to evolve, giving rise to an empowered patient population that is influencing their treatment choices, further stimulating this segment's growth. Invasive Treatment: Dominant vs. Minimally Invasive Treatment: Emerging Invasive treatment options, including hysterectomy and myomectomy, dominate the market due to their long-established protocols and effectiveness in fibroid removal. These treatments, while effective, often involve longer recovery times and greater risks, influencing patient choices. In contrast, minimally invasive treatments, such as laparoscopic procedures and uterine artery embolization, are emerging as popular alternatives. Their key advantages include shorter hospital stays, reduced pain, and quicker recovery, appealing to many patients. This shift towards less invasive methods reflects broader trends in healthcare, emphasizing patient comfort and recovery, and indicates a significant potential for growth within the minimally invasive segment as it adapts to meet the demands of clinicians and patients alike. ## Competitive Benchmarking The uterine fibroid-treatment-device market is characterized by a dynamic competitive landscape, driven by increasing awareness of women's health issues and advancements in medical technology. Key players such as Medtronic (US), Hologic (US), and Boston Scientific (US) are at the forefront, focusing on innovation and strategic partnerships to enhance their market presence. Medtronic (US) emphasizes the development of minimally invasive solutions, while Hologic (US) leverages its expertise in diagnostic imaging to create integrated treatment options. Boston Scientific (US) is actively pursuing collaborations with healthcare providers to expand its product offerings, thereby shaping a competitive environment that prioritizes patient-centric solutions and technological advancements.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive innovation and set industry standards. This competitive structure fosters an environment where smaller firms may struggle to keep pace with the rapid advancements and regulatory requirements dictated by larger entities. In October Medtronic (US) announced the launch of a new uterine fibroid treatment device that utilizes advanced imaging technology to improve procedural accuracy. This strategic move is likely to enhance patient outcomes and solidify Medtronic's position as a leader in the market. The integration of cutting-edge imaging capabilities not only differentiates their product but also aligns with the growing trend towards precision medicine in gynecological treatments. In September Hologic (US) expanded its product line by acquiring a startup specializing in AI-driven diagnostic tools for uterine fibroids. This acquisition is indicative of Hologic's commitment to integrating artificial intelligence into its offerings, potentially revolutionizing the way fibroids are diagnosed and treated. By enhancing its technological capabilities, Hologic positions itself to meet the evolving needs of healthcare providers and patients alike. In August Boston Scientific (US) entered into a partnership with a leading telehealth provider to facilitate remote consultations for patients with uterine fibroids. This collaboration reflects a growing trend towards digital health solutions, enabling patients to access care more conveniently. By embracing telehealth, Boston Scientific not only expands its reach but also aligns with the increasing demand for accessible healthcare services. As of November the competitive trends in the uterine fibroid-treatment-device market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, patient outcomes, and supply chain reliability. This shift suggests that companies that prioritize innovation and strategic partnerships will be better positioned to thrive in an increasingly complex market. ## Recent News & Developments The US Uterine Fibroid Treatment Device Market has seen notable developments recently, particularly with advancements in minimally invasive technologies. Companies like Hologic and Medtronic have been focusing on enhancing their product offerings for uterine fibroid treatment, driving market growth. In September 2023, it was reported that Boston Scientific expanded its product portfolio with a new device aimed at effective fibroid management, which has positively impacted their market valuation. Current affairs indicate a growing emphasis on personalized medicine, influencing companies such as Stryker and Merit Medical Systems to invest in Research and Development initiatives tailored for individualized treatment solutions. Recent merger and acquisition activities in this sector include Johnson and Johnson's acquisition of a start-up specializing in uterine health devices in August 2023, enhancing their strategic positioning in the market. The increase in healthcare expenditure in the US, particularly for women's health, has further propelled the market's expansion. Historical developments, such as the FDA's approval in April 2022 for innovative fibroid treatment devices, underscore the evolving landscape, reinforcing market players' commitment to advancing therapeutic options for patients suffering from uterine fibroids. ## Report Scope | MARKET SIZE 2024 | 1547.08(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1705.03(USD Million) | | MARKET SIZE 2035 | 4507.52(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.21% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Medtronic (US), Boston Scientific (US), Hologic (US), Abbott (US), Johnson & Johnson (US), Stryker (US), Bayer (DE), Merck (DE), Siemens Healthineers (DE) | | Segments Covered | Technology, Mode of Treatment | | Key Market Opportunities | Advancements in minimally invasive technologies enhance treatment options in the uterine fibroid-treatment-device market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the uterine fibroid-treatment-device market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US uterine fibroid-treatment-device market?** A: The market valuation was $1547.08 Million in 2024. **Q: What is the projected market valuation for the US uterine fibroid-treatment-device market by 2035?** A: The projected valuation for 2035 is $4507.52 Million. **Q: What is the expected CAGR for the US uterine fibroid-treatment-device market during the forecast period?** A: The expected CAGR during 2025 - 2035 is 10.21%. **Q: Which companies are considered key players in the US uterine fibroid-treatment-device market?** A: Key players include Medtronic, Boston Scientific, Hologic, Abbott, Johnson & Johnson, Stryker, Bayer, Merck, and Siemens Healthineers. **Q: What are the main segments of the US uterine fibroid-treatment-device market?** A: The main segments include Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, and Embolization Techniques. **Q: How did the Surgical Techniques segment perform in 2024?** A: The Surgical Techniques segment was valued at $300.0 Million in 2024 and is projected to reach $850.0 Million. **Q: What is the valuation range for Minimally Invasive Treatment in the US uterine fibroid-treatment-device market?** A: The Minimally Invasive Treatment segment is expected to range from $800.0 Million to $2500.0 Million. **Q: What is the valuation for Ablation Techniques in the US uterine fibroid-treatment-device market?** A: Ablation Techniques had a valuation of $500.0 Million in 2024, with a projected increase to $1300.0 Million. **Q: What does the market data suggest about the growth of Non-invasive Treatment?** A: Non-invasive Treatment was valued at $447.08 Million in 2024 and is expected to grow to $1157.52 Million. **Q: How does the Embolization Techniques segment compare to other treatment modalities?** A: The Embolization Techniques segment was valued at $347.08 Million in 2024, with a projected growth to $1267.52 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-uterine-fibroid-treatment-device-market-18966*